BioMarin launches Orapred in United States through Alliant Pharmaceuticals

By E. Janene Geiss

Philadelphia, Aug. 28 - BioMarin Pharmaceutical Inc. announced Monday that Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets), the first Food and Drug Administration-approved orally disintegrating tablet form of prednisolone, is now commercially available in the United States.

The Orapred product line, which includes Orapred ODT and Orapred (prednisolone sodium phosphate oral solution) is marketed by Alliant Pharmaceuticals, Inc. under a North American license and acquisition agreement entered into on March 15, according to a company news release.

Orapred is prescribed primarily for acute exacerbations of asthma in children and also is used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer.

Orapred ODT uses a proprietary orally disintegrating tablet technology to provide a taste-masked, non-refrigerated and convenient formulation of prednisolone, officials said.

Under the agreement, BioMarin said it has received a $4 million milestone payment in association with product launch and will receive a final $4 million milestone payment on June 1, 2007, the one-year anniversary of the approval of Orapred ODT.

Additionally, BioMarin said it will receive royalties on Orapred products sales. BioMarin said it will retain commercial rights to the Orapred product line outside of North America.

BioMarin is a Novato, Calif., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.